Effect of Nitrous Oxide on Aggression.

Sponsor
Ohio State University (Other)
Overall Status
Recruiting
CT.gov ID
NCT06118567
Collaborator
National Institute of Mental Health (NIMH) (NIH)
50
1
2
35.8
1.4

Study Details

Study Description

Brief Summary

The goal of this experimental medicine clinical trial is to test the hypothesis that nitrous oxide inhalation will result in a change in neurocircuit function in healthy controls and in individuals with impulsive aggressive tendencies. The main question aims to answer are: Does Nitrous Oxide normalize brain circuit function in impulsively aggressive individuals 24 hours after inhalation. Participants will undergo a 60 minute inhalation session with 50% Nitrous Oxide (or room air at another session) and then undergo an fMRI scan 24 hours later. Researchers will compare healthy controls and impulsively aggressive individuals to see if Nitrous Oxide can normalize the function of cortico-limbic circuits in the latter group.

Condition or Disease Intervention/Treatment Phase
  • Drug: Nitrous oxide
  • Drug: Room Air
Phase 2

Detailed Description

This study is designed to see if inhalation of 50% nitrous oxide (N2O) also known as laughing gas, can normalize cortico-limbic circuit functioning in impulsively aggressive human subjects. If the study results are positive, it would allow further studies of this potential treatment modality for those with recurrent, problematic, impulsive aggressive behavior (Intermittent Explosive Disorder: IED). IED is a disorder in which there are frequent and sudden outbursts of anger (yelling, throwing and breaking things, hitting people) that lead to problems with other people socially or at work. It affects about 4% of the US population lifetime, and does not have any approved treatments. The study will test if N2O can normalize brain activity 24 hours after infusion, in participants with a diagnosis of IED compared with healthy, non-aggressive, controls. This is a double-blinded-randomized study with comparison between groups (controls and IED patients) and comparison for each participant between N2O and placebo (air) inhalation. Participants will receive one type of inhalation 24 hours before undergoing an fMRI. Participants will be randomized to the order in which they receive N2O or air. Participants and study personnel involved in collection of outcome measures will be blinded to the type of inhalation. The study includes up to 7 visits. Visits 1/2 include interviews and questionnaires. At visits 3 and 5, participants receive the N2O or air inhalation. At visits 4 and 6, participants undergo fMRI while completing computer tasks. Visit 7 is to assure data collection is complete.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Masking Description:
Room air (vs. Nitrous Oxide Inhalation)
Primary Purpose:
Basic Science
Official Title:
Nitrous Oxide and Cortico-Limbic Function in Aggression
Actual Study Start Date :
Sep 6, 2022
Anticipated Primary Completion Date :
Aug 31, 2025
Anticipated Study Completion Date :
Aug 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Nitrous Oxide Inhalation

60 minute session inhaling Nitrous Oxide gas.

Drug: Nitrous oxide
Nitrous oxide gas.

Sham Comparator: Room Air

60 minute session inhaling Room Air.

Drug: Room Air
Room Air

Outcome Measures

Primary Outcome Measures

  1. Cortico-Limbic Response to Anger Faces [24 hours after Nitrous Oxide and Room Air]

    Orbito-Frontal and Amygdala responses to Anger Faces in fMRI

  2. Brain Connectivity [24 hours after Nitrous Oxide and Room Air]

    Resting State

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
All participants:
  • Between 21 and 55 years of age.

  • Physically healthy (no clinically significant medical condition as confirmed by medical history/physical exam).

  • Able to give informed consent.

Aggressive (IED) Study Participants (n = 25 Completed; 75 Enrolled).

  • Current DSM-5 Criteria for IED

  • LHA Aggression scores > 12

  • Negative for a history of psychosis, bipolar disorder, developmental disorder, intellectual disability or a current substance use disorder.

Healthy, Non-Aggressive, Controls (n = 25 Completed, 75 Enrolled).

  • Do not meet current/lifetime DSM-5 Criteria for any psychiatric disorder

  • LHA aggression scores < 12

Exclusion Criteria:
  • PCL Screening Version Score > 13; i.e., subject is likely to be psychopathic.32

  • Current DSM-5 Major Depressive Episode.

  • Life history of bipolar disorder/schizophrenia/organic mental syndrome.

  • Intellectual disability [i.e., IQ < 70].

  • History of N2O abuse/dependence.

  • Clinically significant medical condition.

  • Current alcohol/drug use disorder of moderate or severe severity (i.e., subject is not in full remission from moderate to severe alcohol/drug use).

  • Two weeks free of antipsychotic medication. (Note: Because a large number of individuals with aggressive tendencies in the community are already taking SSRIs, SNRIs, or mood stabilizers, these individuals will not be excluded if they continue to report impulsive aggressive behaviors at time of study.)

  • Unwilling/unable to sign informed consent document.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ohio State University Wexner Medical Center Columbus Ohio United States 43210

Sponsors and Collaborators

  • Ohio State University
  • National Institute of Mental Health (NIMH)

Investigators

  • Principal Investigator: Emil Coccaro, M.D., The Ohio State University Wexner Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Emil Coccaro, Professor, Ohio State University
ClinicalTrials.gov Identifier:
NCT06118567
Other Study ID Numbers:
  • 2020H0368
First Posted:
Nov 7, 2023
Last Update Posted:
Nov 7, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Emil Coccaro, Professor, Ohio State University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 7, 2023